Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.

Novartis Investigative Site, St Leonards

Novartis Investigative Site, Liverpool

Novartis Investigative Site, Kogarah

Novartis Investigative Site, Canberra

Novartis Investigative Site, Kingswood

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Fitzroy

Novartis Investigative Site, Geelong

Novartis Investigative Site, South Brisbane

Novartis Investigative Site, Nambour

Novartis Investigative Site, Douglas

Novartis Investigative Site, Adelaide

Novartis Investigative Site, Nedlands

Novartis Investigative Site, Murdoch